Free Newsletter
U.S.-China safety deal goes official soon
Expect lots of smiles and hand-shaking next month, when China and the U.S. are expected to sign a new drug safety pact. Beijing announced today that it will cooperate with the U.S. to ensure the safety of pharmaceuticals, and it's planning a new sweep against false advertising, too. Details of the bilateral agreement weren't forthcoming.
Yesterday, the government trumpeted its ad-quashing strength, citing 33,000 false ads it had swept aside over the last six months. The safety agreement is expected to include a crackdown on exporters and closer scrutiny of drugs old in-country. Whether it will bear more fruit than previous pledges remains to be seen.
- read the report from the Guardian
Related Articles:
Will the FDA get money to flex muscles? Report
U.S., China talk drug safety. Report
Drug-safety hazards many and growing. Report
Americans distrust drugs from China, India. Report
China to overhaul drug safety regulations. Report
Counterfeit drugs plaguing Big Pharma. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: